No Data
No Data
Omeros Analyst Ratings
Omeros Announces Phase 3 Trials For Zaltenibart In PNH With Data Expected In Q4 2026; 120 Sites In 30 Countries Activated; Focus On Intravascular And Extravascular Hemolysis With 8-Week Dosing
Omeros Provides Update on Zaltenibart Trial
Express News | Omeros Corp - No Safety Signal of Concern Has Been Observed With Zaltenibart
Express News | Omeros Corp - Phase 3 Data Needed for Bla Submission Expected in Q4 2026
Express News | Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 Pnh Clinical Trial Program